Elusys Therapeutics, Inc.
about us Elusys & Biodefense product news&events careers
Elusys Overview Leadership
Executive Team Board of  Directors
Anthrax & Bioterrorism Contract Experience Useful Links
Anthim Anthrax Antibody Anthim Publication
Press Releases Presentations
Our Values Working at Elusys Open Positions Benefits Location

NEWS & EVENTS

PRESS RELEASES 2005

2011   2010   2009   2008   2007   2006   2005   2004

 

December 17, 2005

 

Elusys Presents Data on Therapeutic for Staphylococcus Aureus at iCAAC

 

October 19, 2005

 

 

Elusys Therapeutics’ President, Elizabeth Posillico PH.D, Assumes Responsibilities of CEO and Director

 

October 3, 2005



Elusys Therapeutics’ Fast-Tracked Anthrax Drug, Anthim™ Advances into Human Clinical Trials

 

August 3, 2005

Elusys Awarded an Additional $5.4 Million from the US Government for Continued Development of Anthim™

 

April 13, 2005

 

Elusys to Present at Biosquare Conference in France

February 26, 2005

Elusys Submits IND to Initiate Human Studies of Anthrax Drug

 

January 31, 2005

 

Elizabeth Posillico Named President of Elusys

 

 

 

 

 

 

 

 

  • Copyright© 2012 Elusys Therapeutics, Inc. All Rights Reserved.
  • contact us
  • site map
  • careers